Drugs / Pentostatin
Pentostatin
also known as
Nipent · Deoxycoformycin · 2'-Deoxycoformycin · CI-825 · DCF · NSC 218321 · PD 81565 · Pentostatin - Nipent · +3 more
Small molecule targets ADA via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | NIPENT | — | 1993-09-29 | fda.gov ↗ |
| Approved | US (FDA) | NIPENT | — | 1991-10-11 | fda.gov ↗ |
Trials 47
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2006-03-14 | Astex Pharmaceuticals, Inc. | Results SuperGen Announces Results From Combination Study in CLL Published in the Journal of Clinical Oncology astx.com ↗ |
| 2005-12-09 | Astex Pharmaceuticals, Inc. | Results Studies of Nipent® in Combination Cancer Therapies for Treatment of Chronic Lymphocytic Leukemia and Graft-versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting astx.com ↗
The response frequencies were virtually identical in both treatment groups with responses seen in 75% of PCR treated patients and 73% of FCR treated patients and a complete response (CR) achieved in 25% in both studies. |
| 2004-12-06 | Astex Pharmaceuticals, Inc. | Results Studies Exploring Nipent® in Combination Cancer Therapies in the Treatment of Graft-Versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting astx.com ↗
The drug showed particular activity in the treatment of children and adolescents with chronic graft versus host disease (cGVHD), and in high -risk patients undergoing reduced intensity transplantation regimens. |
| 2004-06-10 | Astex Pharmaceuticals, Inc. | Results SuperGen Reports Results of Ongoing Studies of Nipent® in Combination Therapies for Chronic Lymphocytic Leukemia and Low Grade B-cell Lymphomas astx.com ↗
The three studies and their conclusions, which were presented in the General Poster Session, demonstrated that pentostatin used in combination with other chemotherapeutic agents was active, well -tolerated and did not increase the toxicity of the combination regimen. |
| 2004-05-21 | Astex Pharmaceuticals, Inc. | Results SuperGen Announces Study of Novel Regimen Using Nipent® for Hematopoietic Stem Cell Transplantation Published in Journal of Bone Marrow Transplantation astx.com ↗
The study showed that the treatment was well tolerated and associated with a low incidence of transplant -related mortality and acute GVHD. |
| 2004-01-23 | Astex Pharmaceuticals, Inc. | Results Published Data Suggests SuperGen’s Nipent®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome astx.com ↗
Published Data Suggests SuperGen's Nipent ®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome |
All press releases naming this drug 11 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 59 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pentostatin | “Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone...” NCT01460602 ↗52“Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)” NCT02579967 ↗ “such as Etanercept and infliximab, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis” NCT02694770 ↗ “Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days.” NCT02032446 ↗ “e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7” NCT03922724 ↗ “pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4)” NCT00676806 ↗ “Pentostatin 4 mg/m2/day IV on days -11 and -7.” NCT05470491 ↗ “Pazopanib, Pentostatin, Romidepsin” NCT02788201 ↗ “Pazopanib Pentostatin Ponatinib” NCT02551718 ↗ “• Pentostatin” NCT06821542 ↗ |
| Known as | 2'-Deoxycoformycin | “A Phase I Study of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) in Patients With Refractory TdT-Positive Leukemia” NCT00003005 ↗ |
| Known as | CI-825 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Known as | DCF | “Deoxycoformycin (DCF)” NCT00038025 ↗ |
| Known as | Deoxycoformycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00038025 ↗ |
| Known as | Nipent | “Pentostatin (Nipent®) and Alemtuzumab (Campath®)” NCT00698685 ↗ |
| Known as | NSC 218321 | “A Phase I Study of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) in Patients With Refractory TdT-Positive Leukemia” NCT00003005 ↗ |
| Known as | PD 81565 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Known as | Pentostatin - Nipent | “Pentostatin - Nipent” NCT01001780 ↗ |
| Known as | Pentostatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Known as | Pentostatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Known as | YK-176 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Action | Inhibit | “the adenosine deaminase inhibitor pentostatin” NCT00003005 ↗ |
| Modality | Small molecule | “purine nucleoside analogue” PMID 20187101 ↗ May 2010 |
| Route | Intravenous | “pentostatin is administered over 5 minutes by IV bolus” NCT00003005 ↗ |
| Target | ADA | “It is a potent inhibitor of the enzyme adenosine deaminase (ADA)” NCT00496340 ↗ |